Taro Pharma (TARO) Reports Q4 EPS of $3.42

Taro Pharma (NYSE: TARO) reported Q4 EPS of $3.42, versus $4.41 reported last year. Revenue for the quarter came in at $220.4 million, versus $258.3 thousand reported last year.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• S&P 500 may pull back before midterms, but Citi says buy the dip